The Bunsen Reversal: Schrödinger's Physics Agent and the CEO Who Couldn't Stay Skeptical
Schrödinger CEO Ramy Farid launches Bunsen, an LLM-wrapped agent for the company's physics simulations, after years of AI skepticism — early demos cut multi-hour STAT6 analyses to minutes.
Three years ago, Schrödinger CEO Ramy Farid warned that AI hype in drug discovery had reached "dangerous" and "insane" levels. On July 27, 2026, the same executive launched Bunsen — an AI agent that wraps the company's physics-based molecular simulation suite in a large-language-model interface — and told Endpoints News he "couldn't be more pleased to be wrong."
Bunsen is not a new foundation model. It is an orchestration layer: existing Schrödinger tools for molecular dynamics, binding analysis, and cheminformatics, exposed through natural-language prompts backed by domain instructions an off-the-shelf LLM cannot access.
From skunkworks to early access
Endpoints reported that Bunsen began in January as a skunkworks project by longtime Schrödinger machine-learning scientists Karl Leswing and Chris von Bargen. Farid first tried the agent in April and said a protein–protein interaction analysis that took him roughly ten hours over a weekend completed in about five minutes with comparable quality.
Early access rolls out first to existing Schrödinger customers, with a targeted full commercial release by year-end. Customers can plug in their preferred LLM, Farid said.
What Bunsen actually demonstrated
In an office demo described by Endpoints, Farid walked Bunsen through a STAT6 drug-target workflow: retrieving a public protein structure, assessing druggability, designing and refining a molecule, and eventually requesting a "core hop" — a chemist's trick to replace a molecule's middle section and navigate IP constraints.
Two details stood out:
- Tool selection — Bunsen invoked Schrödinger's SiteMap algorithm in "shallow mode," a setting Farid said most users do not know exists, yielding a promising binding score where a standard run might have dismissed STAT6 as undruggable.
- Human steering still required — Farid had to suggest core hopping; Bunsen did not propose the maneuver unprompted.
Business context
Schrödinger ($SDGR) has spent decades building respected simulation software while waiting for broad pharma adoption. Endpoints noted the stock is down more than 70% from a mid-2023 peak, with Wall Street consensus forecasting about $224 million in 2026 revenue.
Farid's pitch is democratization: sophisticated molecular simulation has been trapped behind a small priesthood of expert users. Bunsen aims to lower the skill floor without sacrificing the physics core.
### Sources
- Endpoints News — Exclusive: Schrödinger CEO launches AI agent Bunsen (July 27, 2026)
- PR Newswire — Ono Pharmaceutical partners with Phylo to embed agentic AI (July 28, 2026)